TARA
Protara Therapeutics, Inc.Company with tickers: TARA
CIK
1359931
CUSIP
74365U107
Shares Outstanding
56,204,237
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $19,629,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Research & Development | $13,562,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Operating Income | $-19,629,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Net Income | $-17,782,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Basic) | $-0.31 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Diluted) | $-0.31 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |